Research Management Committee

The Research Management Committee (RMC) is made up of independent members whose primary role is to evaluate research proposals and actively help BioCanRx monitor the progress of its projects.

Independent. International. Leaders

The RMC helps BioCanRx to maintain a robust, competitive research portfolio founded on scientific excellence and network goals. All RMC funding and budget recommendations go to the Board of Directors for approval.

In order to avoid potential conflicts of interest, the voting RMC is composed of independent and primarily international experts in biotherapeutics.

MEMBERSHIP

Dr. Dmitriy Zamarin

Medical Oncologist, Section Head, Gynecologic Medical Oncology at Icahn School of Medicine at Mount Sinai

Dr. Awen Gallimore

Professor, Immunology, Infection and Immunity, Cardiff University

Dr. Jeffrey Hoch

Professor, Department of Public Health Sciences, UC Davis

Dr. Sumithra Mandrekar

Professor of Biostatistics and Oncology at the Mayo Clinic (USA)

Dr. Alan Melcher

Professor of Translational Immunotherapy, The Institute of Cancer Research, Chester Beatty Laboratories, London (UK)

Dr. Isabelle Rivière

Vice President, Head of Oncology Cell Therapy Technologies and Product Engine, Takeda

Dr. Cliona Rooney

Professor, Baylor College of Medicine (USA)

Dr. Bruce Seet

Head of Medical Affairs (Canada) at Novavax

Dr. Len Seymour

Professor of Gene Therapy, University of Oxford

Dr. Alison Betof-Warner

Assistant Professor of Medicine (Oncology), Stanford University School of Medicine

Dr. Guy Ungerechts

Deputy Director of the Medical Oncology Department at the Heidelberg University Hospital and National Center for Tumor Diseases (NCT) Heidelberg

EX-OFFICIO MEMBERS (NON-VOTING)

Dr. John Bell

BioCanRx Scientific Director Senior Scientist, the Ottawa Hospital Research Institute Professor, uOttawa

Dr. Kelvin Chan

Associate Scientist, Sunnybrook Health Sciences Centre (Canada)

Dr. Douglas Mahoney

Associate Professor of Microbiology, Immunology, and Infectious Disease Associate Director, Basic and Translational Research, Charbonneau Cancer Institute Scientific Director, Alberta Cell Therapy and Immune Oncology (ACTION) Initiative Director, Riddell Centre for Cancer Immunotherapy

Dr. Brad Nelson

BioCanRx Theme Leader Director and Distinguished Scientist, Deeley Research Centre, BCCA Professor, Biochemistry and Microbiology, University of Victoria